{"id":"aciphex","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"effect":"Pain","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Infection","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"4.5%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"9.9%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"4.5%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"3.6%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"3.6%","severity":"common","organSystem":""},{"effect":"Taste perversion","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Dry mouth","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Disease of liver","Fracture of bone","Hypomagnesemia","Osteoporosis"],"seriousAdverseEvents":[{"effect":"Hepatitis","drugRate":"","severity":"serious"},{"effect":"Hepatic encephalopathy","drugRate":"","severity":"serious"},{"effect":"Hepatic enzyme increase","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T14:01:38.333011","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Aciphex","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:05:15.847987+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:05:21.384590+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aciphex","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:05:21.719469+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1219/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:05:22.511123+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"1eb38279-0237-4967-be7a-c53a826c1138","title":"ACIPHEX (RABEPRAZOLE SODIUM) TABLET, DELAYED RELEASE [WAYLIS THERAPEUTICS LLC]"},"ecosystem":[],"mechanism":{"target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T02:20:39.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:05:24.085636+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Duodenal Ulcer due to H. Pylori","diseaseId":"duodenal-ulcer-due-to-h.-pylori","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Duodenal ulcer disease","diseaseId":"duodenal-ulcer-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gastroesophageal reflux disease","diseaseId":"gastroesophageal-reflux-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Maintenance of Healing Gastroesophageal Reflux","diseaseId":"maintenance-of-healing-gastroesophageal-reflux","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Multiple endocrine adenomas","diseaseId":"multiple-endocrine-adenomas","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pathological Gastric Hypersecretory Condition","diseaseId":"pathological-gastric-hypersecretory-condition","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Peptic ulcer","diseaseId":"peptic-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic mast cell disease","diseaseId":"systemic-mast-cell-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Zollinger-Ellison syndrome","diseaseId":"zollinger-ellison-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06899061","phase":"PHASE1","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Advanced Solid Malignancies","enrollment":41},{"nctId":"NCT07471867","phase":"PHASE4","title":"Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-03-17","conditions":"Chronic Coronary Syndrome","enrollment":100},{"nctId":"NCT07329972","phase":"PHASE1","title":"A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2025-11-21","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT07408271","phase":"","title":"The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-24","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Eradication Antibiotic","enrollment":83},{"nctId":"NCT07339956","phase":"EARLY_PHASE1","title":"Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-01-10","conditions":"Gastrointestinal Bleeding","enrollment":60},{"nctId":"NCT07358130","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2025-10-21","conditions":"Helicobacter Pylori Infection","enrollment":552},{"nctId":"NCT06349486","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2023-11-28","conditions":"Helicobacter Pylori Eradication","enrollment":390},{"nctId":"NCT04416581","phase":"PHASE4","title":"Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy","status":"RECRUITING","sponsor":"Duk-Woo Park, MD","startDate":"2021-05-12","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome","enrollment":3320},{"nctId":"NCT07284173","phase":"PHASE1","title":"A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-11-03","conditions":"Healthy Adults","enrollment":18},{"nctId":"NCT06399315","phase":"PHASE1","title":"Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers","status":"COMPLETED","sponsor":"Lomond Therapeutics Holdings, Inc.","startDate":"2023-07-28","conditions":"AML","enrollment":112},{"nctId":"NCT06787131","phase":"PHASE1","title":"Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers","status":"COMPLETED","sponsor":"Lomond Therapeutics Holdings, Inc.","startDate":"2024-05-21","conditions":"Healthy","enrollment":104},{"nctId":"NCT05380947","phase":"PHASE1","title":"A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-06-23","conditions":"Healthy","enrollment":13},{"nctId":"NCT06916143","phase":"PHASE1","title":"Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-04-08","conditions":"Healthy Participants","enrollment":48},{"nctId":"NCT07211880","phase":"NA","title":"Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study","status":"COMPLETED","sponsor":"Zero Helicobacter IGAN Network","startDate":"2019-12-05","conditions":"H.Pylori, Gastric Cancer, H Pylori Eradication","enrollment":1043},{"nctId":"NCT05407675","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-08-02","conditions":"Advanced Solid Tumors","enrollment":68},{"nctId":"NCT07010107","phase":"PHASE3","title":"A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.","status":"RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2025-07-30","conditions":"Reflux Esophagitis (RE)","enrollment":500},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT07141381","phase":"PHASE1","title":"A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755","status":"RECRUITING","sponsor":"Voronoi, Inc","startDate":"2025-08-27","conditions":"Healthy","enrollment":24},{"nctId":"NCT07171619","phase":"PHASE1","title":"Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat","status":"RECRUITING","sponsor":"SpringWorks Therapeutics, Inc.","startDate":"2025-09-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT07165444","phase":"NA","title":"Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-09-11","conditions":"Potassium-Competitive Acid Blocker, Proton Pump Inhibitor, Bismuth Based Quadruple Therapy","enrollment":320},{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":"H.Pylori Infection","enrollment":700},{"nctId":"NCT07122024","phase":"PHASE4","title":"Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-02-19","conditions":"Helicobacter Pylori","enrollment":414},{"nctId":"NCT07076914","phase":"PHASE2","title":"Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2025-10-02","conditions":"Primary Lung Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":58},{"nctId":"NCT04448028","phase":"PHASE4","title":"Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-04-22","conditions":"Liver Cirrhosis","enrollment":476},{"nctId":"NCT06105983","phase":"PHASE1","title":"A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-11-03","conditions":"Healthy","enrollment":40},{"nctId":"NCT03897244","phase":"PHASE4","title":"Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-05-30","conditions":"Helicobacter Pylori Infection","enrollment":603},{"nctId":"NCT06417229","phase":"PHASE1","title":"Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants","status":"COMPLETED","sponsor":"Celgene","startDate":"2024-05-28","conditions":"Healthy Participants","enrollment":102},{"nctId":"NCT02475161","phase":"PHASE1","title":"A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-06","conditions":"Healthy","enrollment":16},{"nctId":"NCT05899829","phase":"PHASE1","title":"Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2023-06-21","conditions":"Cough, Healthy","enrollment":42},{"nctId":"NCT04834752","phase":"","title":"Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2021-05-01","conditions":"COVID-19","enrollment":400000},{"nctId":"NCT06054464","phase":"PHASE1","title":"A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants","status":"COMPLETED","sponsor":"PMV Pharmaceuticals, Inc","startDate":"2023-09-19","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT05918822","phase":"PHASE1","title":"A Study of Maribavir Pediatric Formulation in Healthy Adult Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-07-25","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT05923411","phase":"PHASE1","title":"A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-11","conditions":"Healthy Participants","enrollment":113},{"nctId":"NCT06264440","phase":"PHASE1","title":"A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2024-02-12","conditions":"Healthy Volunteer","enrollment":18},{"nctId":"NCT03320538","phase":"NA","title":"Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases","status":"COMPLETED","sponsor":"Jiangxi University of Traditional Chinese Medicine","startDate":"2017-07-10","conditions":"Peptic Ulcer Disease","enrollment":360},{"nctId":"NCT06481371","phase":"NA","title":"Zuojin Wan Combined With Rabeprazole or Mosapride for the Treatment of Functional Dyspepsia Combined With Depression","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-06-30","conditions":"Functional Dyspepsia, Depression","enrollment":120},{"nctId":"NCT00649194","phase":"PHASE1","title":"Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-08","conditions":"Healthy","enrollment":72},{"nctId":"NCT00648349","phase":"PHASE1","title":"Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT00649493","phase":"PHASE1","title":"Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT06337604","phase":"PHASE1","title":"The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets","status":"COMPLETED","sponsor":"TenNor Therapeutics Inc.","startDate":"2017-10-10","conditions":"Helicobacter Pylori Infection","enrollment":20},{"nctId":"NCT05602597","phase":"PHASE1","title":"HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2022-06-01","conditions":"Relapsed or Refractory Lymphoma","enrollment":59},{"nctId":"NCT05630677","phase":"PHASE1","title":"A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-11-04","conditions":"Healthy Volunteers","enrollment":21},{"nctId":"NCT03237741","phase":"PHASE1","title":"Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2017-08-07","conditions":"Amyotrophic Lateral Sclerosis","enrollment":18},{"nctId":"NCT05446142","phase":"PHASE1","title":"A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-01","conditions":"Healthy","enrollment":18},{"nctId":"NCT06268834","phase":"NA","title":"Is Long-Term Proton Pump Inhibitor Use a Cause of Leaky Gut Syndrome","status":"COMPLETED","sponsor":"Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital","startDate":"2023-10-04","conditions":"Proton Pump Inhibitor Adverse Reaction","enrollment":75},{"nctId":"NCT04703868","phase":"PHASE1","title":"A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Yungjin Pharm. Co., Ltd.","startDate":"2021-01-13","conditions":"Gastroesophageal Reflux Disease","enrollment":88},{"nctId":"NCT05879029","phase":"PHASE4","title":"Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2023-07-01","conditions":"Laryngopharyngeal Reflux","enrollment":72},{"nctId":"NCT06076694","phase":"PHASE2","title":"Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2022-06-26","conditions":"Helicobacter Pylori Infection","enrollment":80},{"nctId":"NCT06076681","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2021-09-27","conditions":"Helicobacter Pylori Infection","enrollment":40},{"nctId":"NCT06126029","phase":"PHASE2","title":"Effect of Metformin as Add-on Therapy to Ibuprofen on Disease Activity in Knee Osteoarthritis Patients.","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-10-15","conditions":"Knee Osteoarthritis, Metformin","enrollment":68},{"nctId":"NCT02407119","phase":"PHASE3","title":"Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2003-06","conditions":"Helicobacter Pylori Infection, Early Gastric Cancer, Endoscopic Resection","enrollment":470},{"nctId":"NCT02547025","phase":"NA","title":"Personalized Treatment for Refractory H Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2012-08-01","conditions":"Helicobacter Pylori Infection","enrollment":126},{"nctId":"NCT03779074","phase":"PHASE3","title":"Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2018-09-03","conditions":"Helicobacter Pylori Infection","enrollment":918},{"nctId":"NCT05624229","phase":"PHASE4","title":"Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2023-10-01","conditions":"Upper Gastrointestinal Hemorrhage","enrollment":672},{"nctId":"NCT06037122","phase":"","title":"Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09","conditions":"Helicobacter Pylori Infection","enrollment":558},{"nctId":"NCT05930119","phase":"PHASE1","title":"HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2023-03-17","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":24},{"nctId":"NCT06004401","phase":"NA","title":"The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-08-20","conditions":"The Eradication Rate of Helicobacter Pylori","enrollment":400},{"nctId":"NCT01321567","phase":"","title":"Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-01-01","conditions":"Refractory Reflux Esophagitis","enrollment":2157},{"nctId":"NCT02135107","phase":"PHASE3","title":"A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2013-09","conditions":"Gastroesophageal Reflux Disease","enrollment":517},{"nctId":"NCT05893849","phase":"","title":"Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-03-28","conditions":"Aging","enrollment":624},{"nctId":"NCT05870397","phase":"NA","title":"Optimal Recheck Time for Helicobacter Pylori Eradication: A Prospective Randomized Trial","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-04-21","conditions":"Helicobacter Pylori Eradication","enrollment":900},{"nctId":"NCT05718609","phase":"PHASE4","title":"Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-01","conditions":"Helicobacter Pylori Infection","enrollment":855},{"nctId":"NCT05330858","phase":"PHASE1","title":"Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants","status":"COMPLETED","sponsor":"Alumis Inc","startDate":"2022-03-17","conditions":"Pharmacokinetics","enrollment":14},{"nctId":"NCT04564612","phase":"PHASE1","title":"Study of BIIB091 Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2020-09-28","conditions":"Healthy Volunteers","enrollment":59},{"nctId":"NCT05699070","phase":"PHASE1","title":"Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-02-15","conditions":"Drug-drug Interaction","enrollment":24},{"nctId":"NCT04923113","phase":"NA","title":"Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-06-28","conditions":"Helicobacter Pylori Infection","enrollment":281},{"nctId":"NCT05571787","phase":"PHASE1","title":"HMPL-523 Food Effect and Proton Pump Inhibitor Study","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2022-07-13","conditions":"Relapsed or Refractory Lymphoma","enrollment":26},{"nctId":"NCT05419674","phase":"PHASE4","title":"Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-08-01","conditions":"Helicobacter Pylori Infection","enrollment":393},{"nctId":"NCT02986685","phase":"PHASE4","title":"Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole","status":"WITHDRAWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2016-11","conditions":"Refractory Reflux Esophagitis","enrollment":""},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959},{"nctId":"NCT05014334","phase":"PHASE4","title":"Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2021-12-01","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":300},{"nctId":"NCT04697186","phase":"PHASE4","title":"Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2021-01-07","conditions":"Dyspepsia, Chronic Gastritis, Gastric Cancer","enrollment":524},{"nctId":"NCT01287091","phase":"PHASE1","title":"A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-10-14","conditions":"Healthy Volunteer","enrollment":46},{"nctId":"NCT05208268","phase":"","title":"A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2020-07-23","conditions":"Stomach Ulcer, Duodenal Ulcer","enrollment":676},{"nctId":"NCT04723472","phase":"NA","title":"Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment","status":"SUSPENDED","sponsor":"Shanghai East Hospital","startDate":"2023-08-01","conditions":"Helicobacter Pylori Infection","enrollment":82},{"nctId":"NCT05604261","phase":"PHASE2","title":"A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis","status":"UNKNOWN","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-12","conditions":"Reflux Esophagitis, Gastroesophageal Reflux, Esophagitis","enrollment":156},{"nctId":"NCT05320133","phase":"NA","title":"Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2022-06-20","conditions":"Helicobacter Pylori Infection","enrollment":80},{"nctId":"NCT05364619","phase":"NA","title":"Qingre Huashi Granules Combined the Modified Dual Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2022-08-05","conditions":"Helicobacter Pylori Infection","enrollment":160},{"nctId":"NCT05152004","phase":"NA","title":"Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2018-09-01","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT03530995","phase":"PHASE1","title":"Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers","status":"COMPLETED","sponsor":"Kadmon Corporation, LLC","startDate":"2018-04-09","conditions":"Drug-drug Interaction, Autoimmune Diseases, Fibrotic Disease","enrollment":73},{"nctId":"NCT04944771","phase":"PHASE1","title":"Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-07-26","conditions":"Solid and Hematological Malignancies","enrollment":48},{"nctId":"NCT00838526","phase":"PHASE3","title":"Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-08-31","conditions":"Gastroesophageal Reflux Disease (GERD)","enrollment":240},{"nctId":"NCT03094416","phase":"PHASE4","title":"Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2018-07-30","conditions":"Hypothyroidism;Postablative","enrollment":66},{"nctId":"NCT04157881","phase":"PHASE4","title":"A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2020-01-03","conditions":"Atrial Fibrillation, Venous Thromboembolism","enrollment":46},{"nctId":"NCT05226819","phase":"NA","title":"Influencing Factors of Helicobacter Pylori Infection and Eradication Failure","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","startDate":"2022-02-06","conditions":"Helicobacter Pylori Infection","enrollment":300},{"nctId":"NCT05191888","phase":"PHASE4","title":"14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2021-08-06","conditions":"Helicobacter Pylori Eradication","enrollment":906},{"nctId":"NCT04565574","phase":"PHASE1","title":"A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-16","conditions":"Healthy Participants","enrollment":42},{"nctId":"NCT05061732","phase":"PHASE4","title":"Helicobacter Pylori Eradication and Follow-up","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-09-30","conditions":"Helicobacter Pylori Infection","enrollment":4447},{"nctId":"NCT05023577","phase":"PHASE4","title":"Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08-26","conditions":"Helicobacter Pylori Infection","enrollment":504},{"nctId":"NCT05018923","phase":"PHASE4","title":"Tetracycline Versus Doxycycline for HP Rescue Therapy","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08-24","conditions":"Helicobacter Pylori Infection","enrollment":242},{"nctId":"NCT05014685","phase":"PHASE4","title":"PPI-amoxicillin for H. Pylori Treatment","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08-20","conditions":"Helicobacter Pylori Infection","enrollment":732},{"nctId":"NCT04622358","phase":"PHASE1","title":"A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-12-05","conditions":"Gastroesophageal Reflux Disease","enrollment":43},{"nctId":"NCT04494243","phase":"PHASE1","title":"A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-08-28","conditions":"Gastroesophageal Reflux Disease","enrollment":40},{"nctId":"NCT04645940","phase":"PHASE1","title":"Fruquintinib Food Effect and Proton Pump Inhibitor Study","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2020-09-24","conditions":"Drug Interaction, Food-drug Interaction","enrollment":14},{"nctId":"NCT04510649","phase":"PHASE1","title":"Surufatinib DDI With a PPI and a CYP3A Inducer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2020-07-09","conditions":"Healthy","enrollment":28},{"nctId":"NCT04209933","phase":"PHASE4","title":"Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-05-25","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":240},{"nctId":"NCT00978016","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2009-09","conditions":"Gastroesophageal Reflux Disease","enrollment":460},{"nctId":"NCT04488016","phase":"PHASE1","title":"A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-06-24","conditions":"Bioavailability, B-cell Lymphoid Cancer","enrollment":54},{"nctId":"NCT04564040","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-12","conditions":"Mantle Cell Lymphoma, COVID-19","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1219"},"formularyStatus":[],"_approvalHistory":[{"date":"20000508","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20000216","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20110520","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20220304","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20141015","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20130419","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"19990819","type":"ORIG","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20030801","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20120508","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20080630","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20020923","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20050603","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20020529","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20011002","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20020212","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20001215","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20180607","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20000228","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20161024","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20121005","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20000216","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20230718","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20141219","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"19991021","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20201127","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20160404","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20100903","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20020930","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20021108","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20011002","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20010815","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20000920","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"},{"date":"20180109","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA020973"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":12,"therapeuticAreas":["Gastroenterology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Aciphex","genericName":"Aciphex","companyName":"University of Utah","companyId":"university-of-utah","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:05:24.085636+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}